Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($0.45), $0.12 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $17.2 million versus the consensus estimate of $16.75 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.